Evidence map›Paper›PMID 39788940›Full record

ReviewMicrosystems & nanoengineering2025

Microfluidic platforms for monitoring cardiomyocyte electromechanical activity.

Wei Wang, Weiguang Su, Junlei Han, Wei Song, Xinyu Li, Chonghai Xu, Yu Sun, Li Wang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Microsystems & nanoengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Engineering copper ferrite (CuFeMicrosystems & nanoengineering · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wei WangSchool of Mechanical Engineering, Qilu University of Technology (Shandong Academy of Sciences), 250353, Jinan, China.
Weiguang SuSchool of Mechanical Engineering, Qilu University of Technology (Shandong Academy of Sciences), 250353, Jinan, China.
Junlei HanSchool of Mechanical Engineering, Qilu University of Technology (Shandong Academy of Sciences), 250353, Jinan, China.
Wei SongDepartment of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021, Jinan, China.
Xinyu LiDepartment of Minimally Invasive Comprehensive Treatment of Cancer, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 250021, Jinan, China.
Chonghai XuSchool of Mechanical Engineering, Qilu University of Technology (Shandong Academy of Sciences), 250353, Jinan, China.
Yu SunDepartment of Mechanical and Industrial Engineering, University of Toronto, Toronto, ON, M5S3G8, Canada. yu.sun@utoronto.ca.
Li WangSchool of Mechanical Engineering, Qilu University of Technology (Shandong Academy of Sciences), 250353, Jinan, China. liwang@qlu.edu.cn.ORCID http://orcid.org/0000-0002-5166-0397

Funding

National Natural Science Foundation of China (National Science Foundation of China) No. 61901239Taishan Scholar Foundation of Shandong Province No. tsqn201812087
6 · The paper itself

Abstract

Cardiovascular diseases account for ~40% of global deaths annually. This situation has revealed the urgent need for the investigation and development of corresponding drugs for pathogenesis due to the complexity of research methods and detection techniques. An in vitro cardiomyocyte model is commonly used for cardiac drug screening and disease modeling since it can respond to microphysiological environmental variations through mechanoelectric feedback. Microfluidic platforms are capable of accurate fluid control and integration with analysis and detection techniques. Therefore, various microfluidic platforms (i.e., heart-on-a-chip) have been applied for the reconstruction of the physiological environment and detection of signals from cardiomyocytes. They have demonstrated advantages in mimicking the cardiovascular structure and function in vitro and in monitoring electromechanical signals. This review presents a summary of the methods and technologies used to monitor the contractility and electrophysiological signals of cardiomyocytes within microfluidic platforms. Then, applications in common cardiac drug screening and cardiovascular disease modeling are presented, followed by design strategies for enhancing physiology studies. Finally, we discuss prospects in the tissue engineering and sensing techniques of microfluidic platforms.

Identifiers

PMID39788940
PMCPMC11718118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.